IDHIFA® is a prescription medicine used to treat people with acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation whose disease has come back or has not improved after previous treatment(s). It is not known if IDHIFA is safe and effective in children.
This website is best viewed using the horizontal display on your tablet device.
This website is best viewed using the vertical display on your mobile device.
IDHIFA® is the first and only treatment
option for IDH2-mutated AML that has come back or not improved after previous treatment